FDAnews Drug Daily Bulletin

ROCHE SAYS NO REASON FOR BREACH OF TAMIFLU PATENT IN TAIWAN

Nov. 29, 2005
A A

Roche Holding AG said it is optimistic about meeting its contractual obligations and being able to supply Taiwan with all the Tamiflu it requires. A breach of the compulsory license agreement, as had been announced by Taiwanese officials earlier today, is therefore not necessary, a spokesman for the company said. Other Asian countries also interested in Tamiflu production -- such as Thailand, the Philippines and Indonesia -- where Roche partner Gilead Sciences Inc has not requested patent protection, are free to go ahead with production of the drug, deemed as first-line treatment in the event of a bird-flu pandemic.

Forbes (http://www.forbes.com/markets/feeds/afx/2005/11/28/afx2354885.html)